The drug company, which is born with a "golden spoon", is set to go on sale on Hong Kong's main board.

"Pharmaceutical Network Enterprise News" recently reported that the drug Ming Juno on August 14 formally submitted an IPO application to the Hong Kong Stock Exchange.
proposed to raise $230m (about HK$1.55bn-HK$2.33bn) in the IPO, co-sponsors Goldman Sachs and UBS.
public information, drug meth is a clinical stage cell therapy company founded in 2016 by Juno Therapeutics and Pharmaceutical Mingkangde.
the agreement, the two sides each hold a 50% stake in the drug.
can say that this is a "golden spoon" born in the pharmaceutical company.
more than four years since the company was founded, it has also been favored by pharmaceutical investment institutions.
the listing, Pycnamine completed a $90 million round A financing in March 2018 and a $100 million round B financing in June 2020.
, Temasek, Sequoia Capital, CPE, Future Assets and other investment institutions are its investors.
2018, 2019 and the first half of 2020, according to the prospectau, the research and development expenditure of Pharmaceutical Ming-Juno was RMB 760 million, RMB 136 million and RMB 0.82 billion, respectively, with corresponding net losses of RMB273 million, RMB633 million and RMB650 million, respectively.
As of August 5 this year, there are seven candidates for cell immunotherapy for hematomas and solid tumors in the pharmaceutical products pipeline, as well as several products in potential product pipelines.
among them, on the CAR-T circuit, the main candidate for the drug, CD19-targeted CAR-T product Ricky Rylman (JWCAR029), is highly anticipated and watched.
the product was approved by the State Drug Administration CDE in June this year, which is also the second CAR-T therapy to submit a listing application.
In December 2019, at the 61st Annual Meeting of the American Society of Hematology (ASH), Pythono announced data from the JWCAR029 Clinical Trials for the Treatment of Adult Recurrence/Difficult B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL Phase I Clinical Trials), which showed that the product was safe and effective.
, car-T therapy has become a very popular track in biomedicine in recent years, and its market size is expanding.
car-T market is expected to grow to $4.7 billion by 2024, according to data from the Global Car-T Market.
will grow at a compound annual rate of 45.3% from 2019 to 2024.
car-T market is huge and is expected to reach RMB600 million by 2021.
is expected to reach RMB5.4 billion by 2024 as the number of cancer patients in the country increases and medical expenses increase.
in the face of the huge market blue sea, domestic pharmaceutical companies are also making efforts.
As of July 31, 2020, more than 11 companies had developed CAR-T therapies for clinical trials with CD19 as their target, according to analysis data from the National Drug Administration's Drug Review Center (CDE) and Frost Sullivan.
However, in terms of the process, there is currently no CAR-T therapy approved in China, and the drug Ming Juno's JWCAR029 and Fosun Kate's FKC876 are expected to become China's first approved CAR-T therapy.
is understood that the funds raised after the listing will be used for product development, new potential acquisitions and the introduction of licensing opportunities, company operations and general corporate purposes, focusing on JWCAR029 research and development, future sales in the Chinese market and other candidate products (including the JWATM203 project, JWATM204 project and Nex-G) research and development activities.
In addition to the power CAR-T field, on July 20 this year, Pharmaceuticals announced the acquisition of Syracuse Biopharma (Hong Kong) and the acquisition of Eureka Therapeutics' proprietary antibody, the TCR (AbTCR) ARTEMIS project and the development and commercialization of solid tumor technology in China and ASEAN countries.
the industry believes the move could mean that the drug meth could be laid out in the TCR field through collaboration.
.